ArticleOpen heart2025
Risk factor monitoring, management and use of prevention medicines in those with a history of premature coronary heart disease.
Article in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThose with premature coronary heart disease (pCHD) have a lower 5-year risk of repeat events; however, their lifetime risk is high. The aim of this study was to assess secondary prevention (SP) medical therapy and risk factor (RF) monitoring in patients with pCHD compared with those without pCHD.
methodsAnalysis of a national primary care database including patients attending the same practice between January 2015 and March 2021 with at least 3 follow-up appointments, a history of CHD and a follow-up duration of at least 2 years. pCHD was defined as males under 55 and females under 65 at age of diagnosis of their CHD.
resultsAmong the 64 704 with CHD, 21 035 (32.5%) had pCHD (10 339 women <65 years of age and 10 696 men <55 years of age). Patients with pCHD compared with non-pCHD were more likely to be smokers (59.4% vs 52.6%, p<0.001), less likely to have hypertension (61.9% vs 73.2%, p<0.001) and similar rates of dyslipidaemia (57.8% and 57.5%, p=0.806) and diabetes (30.8% vs 30%, p=0.696). After adjusting for RF, pCHD was not associated with odds of blood pressure (BP) assessment (OR 0.63, 95% CI 0.40 to 1.00), measurement of glycated haemoglobin (OR 0.99, 95% CI 0.94 to 1.04) and any lipid monitoring (OR 1.05, 95% CI 0.96 to 1.14). Patients with PCHD had lower odds of prescription of statins (OR 0.81, 95% CI 0.76 to 0.87), any antiplatelets (OR 0.81, 95% CI 0.77 to 0.86), antihypertensive medication (OR 0.73, 95% CI 0.67 to 0.79) and beta blockers (OR 0.94, 95% CI 0.90 to 0.98) after adjustment for baseline RF. Women with pCHD were even less likely to be prescribed SP medicines of BP lowering and antiplatelets, both p value for interaction <0.000.1
conclusionsPatients with a history of pCHD had similar rates of RF monitoring to patients without pCHD, but patients with pCHD were less likely to be prescribed SP medication of statins, antihypertensives and antiplatelets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.